The Room Was Full. The Momentum Is Real.
|
The 2026 iC³ Life Science & Healthcare Innovation Summit brought the North Texas life sciences community together in Arlington for two extraordinary days of connection, conversation and possibility.
Across the Summit, leaders from industry, research, healthcare, investment, entrepreneurship and economic development came together not simply to discuss where our ecosystem is headed, but to help shape what comes next.
From new relationships and emerging companies to conversations around commercialization, manufacturing, investment, workforce and the technologies transforming healthcare, iC³ reflected a North Texas ecosystem growing in both scale and ambition.
To every speaker, sponsor, partner, exhibitor, volunteer and attendee who helped make this year’s Summit possible: thank you for being in the room.
The Summit may be over, but the work continues — and so does the momentum.
|
Thank you to our sponsors
|
Breaking News from iC³:
Rainwater Charitable Foundation Launches BRING IT
Applications due November 13, 2026
|
One of the most important announcements from this year’s iC³ Summit came directly from the stage.
Glenn A. Harris of the Rainwater Charitable Foundation introduced the Brain Research & Innovation Network: Grant Initiative of Texas (BRING IT), a new funding opportunity designed to advance brain health and dementia research across Texas.
BRING IT will provide approximately 20 one-year seed grants of up to $100,000 to Texas-based academic and nonprofit teams. The initiative is designed to help promising research move forward while positioning projects for future funding opportunities through the Dementia Prevention and Research Institute of Texas (DPRIT).
BioNTX was proud that this opportunity was first shared with the North Texas life sciences community at iC³. We are especially grateful to the Rainwater Charitable Foundation, a key iC³ sponsor and partner, and to Glenn Harris for bringing this announcement to the Summit and helping expand awareness of new opportunities to advance dementia research and brain health across Texas.
|
This Is Our Story: The BioNTX Anthem Film
|
At iC³ 2026, we debuted something special.
The new BioNTX Anthem Film captures more than an organization. It captures a region in motion — the people, institutions, companies and communities building the future of life sciences and healthcare across North Texas.
Our ecosystem has grown because people across this region have chosen to build together, connect across traditional boundaries and believe in what North Texas can become.
Produced in partnership with DHD Films, BioNTX’s Official Storytelling & Content Production Partner, the Anthem Film brings that journey to life.
This is our community. This is our moment. This is BioNTX.
|
North Texas Takes the Global Innovation Stage at AURP IC2026
|
Just days after the conclusion of the 2026 iC³ Life Science & Healthcare Innovation Summit, the momentum continues as North Texas welcomes the Association of University Research Parks (AURP) International Conference to Pegasus Park in Dallas.
Bringing together more than 300 leaders from research parks, innovation districts, universities, economic development organizations and industry, IC2026 provides another opportunity to showcase the collaboration, infrastructure and ideas driving our region forward.
BioNTX is proud to welcome this international community to North Texas and to share the story of an ecosystem increasingly connected across life sciences, healthcare, research, commercialization and economic development.
The timing could not be more fitting: from iC³ in Arlington to AURP at Pegasus Park, North Texas is demonstrating the power of a region building, connecting and growing together.
|
Texas Leads the Way as ARPA-H Launches SURPASS Initiative
|
BioNTX CEO Gina Ford attended the announcement by the nation’s top health officials of a new ARPA-H initiative to streamline clinical trials in the U.S.
“Texas represents the United States in one state and has everything needed to move the ball forward,” said ARPA-H Director Alicia Jackson, PhD, pointing to incredible innovation, medical research institutions, and willingness to be a pioneer and partner. The Sept. 30 rollout took place at UT Austin’s Dell Medical School.
“Given everything our state is doing to support the success of life-changing innovation for patients, it is thrilling to see Texas at the forefront of this transformational project,” said Ford, noting this comes exactly three years after ARPA-H selected Texas for its Customer Experience Hub at Pegasus Park.
The new ARPA-H SURPASS program will evaluate drugs and biologics more efficiently and remove barriers that slow clinical development.
|
BioNTX CEO Gina Ford on the Future of North Texas Life Sciences
|
North Texas is emerging as a growing hub for biotech, life sciences, and healthcare innovation.
In this episode of Learning From Leaders, Lili Clark speaks with Gina Ford, CEO of BioNTX, about strengthening the region’s life sciences ecosystem, supporting commercialization, connecting innovators with resources, and advancing patient impact.
The conversation also highlights the growth of the iC³ Life Science & Healthcare Innovation Summit and the importance of building the infrastructure needed to support North Texas’ future.
|
Building the Workforce Infrastructure for What Comes Next
|
On October 2, the BioNTX Facilities Committee brought together leaders from higher education, workforce development and the built environment for a BioNTX Presents: North Texas Workforce Development Panel at BioLabs.
Moderated by Ben Magill of the Texas Talent Accelerator at the University of North Texas, the discussion explored the facilities, programs and collaborative models helping North Texas prepare the talent needed to support the region’s growing life sciences ecosystem.
The expert panel included Diego Rozo, Managing Principal, Perkins&Will; Logan Ardrey, Assistant Director, Texas A&M NCTM2 Lab; Bridgette Kirkpatrick, Biotechnology Coordinator, Collin College; and Todd Polk, Professor of Practice, UTDesign at The University of Texas at Dallas.
The conversation highlighted the connection between workforce development and the places where people learn, train and gain hands-on experience, while also identifying opportunities to better connect regional resources with employers, educators, students and professionals. The morning also included networking and a tour of the Texas A&M NCTM2 Lab.
The program reflects a larger BioNTX priority for 2027: bringing North Texas workforce efforts together through a more comprehensive platform that expands access to talent, opportunities, resources and collaboration.
North Texas already has many of the pieces required to build a world-class life sciences workforce. The next opportunity is to connect them.
That work is already underway.
|
BMK Pharma Expands Manufacturing in North Texas
|
BioNTX was pleased to attend the BMK Pharma Sign Reveal at the site of their upcoming 50,000-square-foot manufacturing facility in Allen, TX. Led by Founder Dr. Jay Bhaumik, BMK Pharma is developing a 503B sterile outsourcing facility that will produce high-quality compounded medications under cGMP standards once operational.
This investment is a meaningful step forward for pharmaceutical manufacturing in North Texas, expanding regional capacity and strengthening the infrastructure that supports healthcare providers with reliable, high-quality medications. BioNTX congratulates Dr. Bhaumik and the BMK Pharma team on this exciting milestone and looks forward to the impact this facility will have on regional biomanufacturing.
|
BIO BREAK: Connect, Collaborate, Innovate
|
BIO BREAK brings the life sciences community together for an evening of connection and conversation. Attendees will have the opportunity to network with peers, share insights on emerging trends, and explore ideas driving collaboration and innovation across the ecosystem. The event is designed to strengthen professional relationships and support a more connected life sciences community in the region.
|
FORT WORTH
October 13, 2026
|
Alloy Therapeutics Joins
World Economic Forum’s Unicorns Community
|
Alloy Therapeutics has been selected to join the World Economic Forum’s Unicorns Community, recognizing the company’s growth and role in advancing drug discovery and development. Through its AI enabled biotechnology infrastructure and Product Development Organization model, Alloy supports partners in developing therapeutics across areas including antibodies, genetic medicines, cell therapies, and drug delivery.
|
AstraZeneca and Summit Therapeutics
Expand Cancer Treatment Collaboration
|
AstraZeneca and Summit Therapeutics are collaborating to evaluate ivonescimab in combination with antibody drug conjugates, beginning with sonesitatug vedotin in gastrointestinal cancers. The companies also plan to explore additional combinations across tumor types, bringing together targeted cancer therapies and next generation immunotherapy.
|
ClearSight Therapeutics Receives NIH Award
to Advance Eye Disease Research
|
Dallas-based ClearSight Therapeutics has received a National Eye Institute SBIR Phase I award to support research into a preservative-free ophthalmic formulation for acute infectious conjunctivitis and epidemic keratoconjunctivitis (EKC). The one-year research program will generate data to further evaluate the technology and support its potential advancement toward clinical development.
|
Colossal Foundation and IUCN SSC Partner
to Advance Technology in Species Conservation
|
The Colossal Foundation and IUCN Species Survival Commission have announced a four year partnership to expand the responsible use of advanced technologies in global species conservation. The collaboration will support modernizing conservation assessments, funding overlooked species, strengthening the IUCN SSC network, and evaluating tools including AI, genome sequencing, and other emerging technologies for conservation applications.
|
Etira Reports Patient Reaches More Than
One Year on ERX-315 in Phase 1 Trial
|
Etira announced that a patient with advanced cancer has remained on treatment with investigational ERX-315 for more than one year in the company’s ongoing Phase 1 clinical trial. The study is evaluating the safety and tolerability of ERX-315 in patients with advanced solid tumors whose cancers have stopped responding to approved systemic therapies.
|
Johnson & Johnson Reports Long-Term IMAAVY Data
in Generalized Myasthenia Gravis
|
Johnson & Johnson announced new clinical findings for IMAAVY in generalized myasthenia gravis, including two-year data in adolescents showing sustained improvements in daily function and muscle strength alongside reductions in corticosteroid use. Additional findings provide insight into treatment transitions among adults with gMG and the need for more consistent disease control.
|
Nanoscope Therapeutics’ MOGENRY Receives
Priority Review in Japan
|
Nanoscope Therapeutics announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has accepted its application for MOGENRY® (MCO-010), an optogenetic gene therapy designed to restore vision in patients with inherited retinal dystrophies, and granted it priority review. The FDA is also reviewing Nanoscope’s application for MOGENRY for retinitis pigmentosa in the United States. The company expects potential regulatory decisions in both markets in the first half of 2027.
|
Opsin Biotherapeutics Awarded NIH Grant
for Chronic Pain Therapy
|
Bedford-based Opsin Biotherapeutics has been awarded a two-year, $2.35 million Phase II SBIR grant from the NIH’s National Institute of Neurological Disorders and Stroke to advance its optogenetic neuromodulation technology for chronic pain. The non-dilutive funding will support IND-enabling development of a non-viral, light-based approach designed to provide a cell-type-selective alternative to traditional electrical spinal cord stimulation.
|
GL Chemtec Expands US Presence and
Advanced Drug Development Capabilities
|
GL Chemtec is expanding its U.S. presence as it advances its complex API, polymer chemistry, and GMP production capabilities for pharmaceutical and medical product development. The company is strengthening its North American operations and customer partnerships while scaling its advanced chemistry platforms and manufacturing capabilities.
|
UTA and Cook Children’s Advance
Brain Health Research Across the Lifespan
|
The University of Texas at Arlington and Cook Children’s are bringing researchers, clinicians, and students together to advance brain health research across all stages of life. The symposium will explore emerging approaches in neuroscience, neuroimaging, artificial intelligence, and precision medicine, with a focus on conditions including epilepsy, stroke, traumatic brain injury, and Alzheimer’s disease.
|
UT Dallas Research Examines Estrogen’s Role in Psychosis
|
A University of Texas at Dallas researcher is studying how estrogen levels during adolescence and early adulthood may influence brain development and the risk of developing psychosis. The NIH funded research will examine long term brain development data to better understand why psychosis often emerges earlier and more severely in men and how estrogen may help delay its onset.
|
UT Southwestern Spinoff Receives CPRIT Grant
to Advance Cancer Immunotherapy
|
MusiQ Bio, a biotech startup founded to advance cancer technology developed at UT Southwestern, has received CPRIT funding to further develop its ultrasound guided immunotherapy platform. The technology uses microbubbles to deliver immune activating agents to tumors, with research underway across multiple cancer types and toward potential clinical trials.
|
UT Tyler and Family Circle of Care Mark 5 Years of Partnership
|
The University of Texas at Tyler School of Medicine and Family Circle of Care are marking five years of collaboration through the West Gentry Clinic in North Tyler. The partnership expands access to healthcare while providing UT Tyler internal medicine residents with hands on training and experience serving the East Texas community.
|
Upcoming Events & Opportunities
|
Building a Trusted Healthcare Business in the Digital Age
Join the Society of Physician Entrepreneurs for a fireside chat with Dr. Sanjay Doddamanni and Dr. Hubert Zajicek exploring the physician founder’s journey and what it takes to build a trusted healthcare business in the digital age. The conversation will cover entrepreneurship, innovation, and the evolving healthcare landscape.
October 15th | Virtual
|
Join To Cure a Rose Foundation for an intimate evening bringing together music and genetic medicine to support efforts to develop life saving treatments for children with rare diseases. The event will feature world touring artist Casey McPherson performing new acoustic material inspired by his family’s journey and work in biotechnology.
October 16th | Austin, TX
|
Join the American Heart Association to support cardiovascular research, education, and community health. With events across Dallas, Fort Worth, and surrounding communities, participants of all ages can take part in family friendly walks while supporting efforts to prevent heart disease and stroke and promote lifesaving CPR awareness.
October 17th | Irving, TX
|
Venture Dallas 2026 Conference
Venture Dallas brings together founders, investors, and business leaders to showcase the DFW Metroplex as a major innovation hub. The conference features high-level keynote speeches, concurrent panel discussions, curated networking, and live startup pitches
October 22nd | Dallas, TX
|
Thank you for your support!
|
|
